Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revlon revises ’06 sales

This article was originally published in The Rose Sheet

Executive Summary

Revlon reports 2006 revenue outlook is now lower than expected, citing "less robust growth" from its Vital Radiance and Almay lines due to "stepped up competitive activity," firm states June 2. The company also reports "less effectiveness" from certain revenue driving actions. While "strong" growth is still expected this year, it will be "lower than previously planned," company notes. Given the revised outlook, the firm now expects adjusted EBITDA to be "at or below 2005 levels, with a significant impact on the second quarter of this year." Revlon reported adjusted EBITDA of $167 mil. in 2005. Additionally, Revlon will defer a $75 mil. equity offering to late 2006 or early 2007, and will defer consideration of the previously announced proposed refinancing of its current credit facility, the company notes. Revlon maintained it will "continue to invest to support and build its brands, while continuing to focus over the long term on improving its margin structure through the company's ongoing productivity initiatives"...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel